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Abstract
Background: Increased tendon production of the inflammatory mediator prostaglandin E2 (PGE2) has been
suggested to be a potential etiologic agent in the development of tendinopathy. Repeated injection of PGE2 into
tendon has been proposed as a potential animal model for studying treatments for tendinopathy. In contrast,
nonsteroidal anti-inflammatory drugs (NSAIDs) which inhibit PGE2 production and are commonly prescribed in
treating tendinopathy have been shown to impair the healing of tendon after acute injury in animal models. The
contradictory literature suggests the need to better define the functional effects of PGE2 on tendon. Our objective
was to characterize the effects of PGE2 injection on the biomechanical and biochemical properties of tendon and
the activity of the animals. Our hypothesis was that weekly PGE2 injection to the rat patellar tendon would lead to
inferior biomechanical properties.
Methods: Forty rats were divided equally into four groups. Three groups were followed for 4 weeks with the
following peritendinous injection procedures: No injection (control), 4 weekly injections of saline (saline), 4 weekly
injections of 800 ng PGE2 (PGE2-4 wks). The fourth group received 4 weekly injections of 800 ng PGE2 initially and
was followed for a total of 8 weeks. All animals were injected bilaterally. The main outcome measurements
included: the structural and material properties of the patellar tendon under tensile loading to failure, tendon
collagen content, and weekly animal activity scores.
Results: The ultimate load of PGE2-4 wks tendons at 4 weeks was significantly greater than control or saline group
tendons. The stiffness and elastic modulus of the PGE2 injected tendons at 8 weeks was significantly greater than
the control or saline tendons. No differences in animal activity, collagen content, or mean fibril diameter were
observed between groups.
Conclusions: Four weekly peritendinous injections of PGE2 to the rat patellar tendon were not found to be an
effective model of clinical tendinopathy. In contrast, improved structural and material properties of the patellar
tendon were found after PGE2 injection. While PGE2 has been thought to have a contributory role in the
development of tendinopathy and anti-inflammatory medications remain a common treatment, our results suggest
a positive role of PGE2 in tendon remodeling in some circumstances.
Background
Tendinopathy is a frequent source of pain and disability
seen in clinical practice. Common sites of tendinopathy
include the rotator cuff, the common extensor origin at
the elbow, the patellar tendon, and the Achilles tendon.
Histologically, tendinopathy is characterized by degenera-
tion and disorganization of collagen fibrils, increased
mucoid ground substance, and the notable absence of
inflammatory cells [1]. In the clinical setting, tendinopathy
ranges from activity related pain to frank rupture. The
pathophysiology behind development of this condition as
well as the optimum treatment remains controversial. An
ideal animal model of tendinopathy would produce similar
histologic findings, would decrease biomechanical strength
of the tendon, could be readily applied to different ana-
tomic areas, and would share a common pathophysiology
to human tendinopathies.
Several theories exist about the pathophysiology behind
the development of tendinopathy, but most involve some
type of cellular response induced by repetitive motions
[2,3]. One theory involves the local release of inflammatory
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mediators by fibroblasts in response to mechanical loading.
Cyclical loading of tendon fibroblasts in vitro has been
shown to increase local concentrations of PGE2 and leuko-
triene B4 [2,3]. Cyclical loading has also been shown to
increase PGE2 and nitric oxide levels in a tendon explant
system [4]. PGE2 has been implicated as a potential etiolo-
gic agent in the development of tendinopathy and as a pos-
sible inducer of degradative enzyme activity [5].
In attempts to determine how local prostaglandin
levels may affect tendon in vivo, a few studies have
investigated local injection of prostaglandin E1 (PGE1)
or PGE2 as an animal model of tendinopathy. Sullo et
al. injected the rat Achilles tendon with PGE1 and found
increased cross sectional area and degenerative changes
similar to human tendinopathy after 5 weeks [6]. Khan
et al. injected PGE2 into rabbit patellar tendons and
found loss of collagen fiber organization and decreased
collagen fibril diameter compared to controls [7]. How-
ever, neither of these studies evaluated the effect of
prostaglandin injection on the tendon biomechanical
properties which are more functionally relevant to the
risk of the tendon degenerating to a state for which the
chance of rupture is elevated.
In contrast to the proposed role of prostaglandins in
tendon degeneration, there exists alternative evidence
that suggests a positive role of prostaglandins in tendon
healing. Several acute tendon injury models have demon-
strated that administration of cyclooxgenase inhibitors
which act to decrease the production of prostaglandins
during the healing period impair the biomechanical prop-
erties of the healing tissue [8,9]. Furthermore, it has been
suggested nonsteroidal anti-inflammatory drugs
(NSAIDs) may negatively influence tendon healing in
tendinopathy and may contribute to the failed healing
response [10]. Recent work has also shown that blockade
of PGE2 production by NSAID intake can abolish exer-
cise-induced increases in collagen synthesis in the human
patellar tendon [11]. Past studies have found local admin-
istration of PGE2 in muscle in rabbits to stimulate fibrous
tissue formation suggesting anabolic effects [12].
The contradictory literature concerning the positive or
negative role of prostaglandins on tendon suggests the
need for studies to better define the functional biomecha-
nical effects of local application of PGE2 on tendon. Our
objective was to characterize the effects of PGE2 injection
on the biomechanical and biochemical properties of ten-
don and the activity of the animals. Our hypothesis was
that weekly PGE2 injection to the rat patellar tendon
would lead to inferior biomechanical properties.
Methods
Animal care and procedure
Protocols were approved by the University Institutional
Animal Care and Use Committee. A total of 40 retired-
breeder female Sprague-Dawley rats (350-500 g) were
obtained from a commercial breeder. Four different
study groups of ten animals each were used. A control
group underwent no injections. The remaining groups
underwent weekly peritendinous injections into both
patellar tendons with a 27 gauge needle and a 100
microliter syringe. The saline group received injection of
50 microliters of 0.9% sodium chloride. The PGE2-4 wks
and PGE2-8 wks groups had injections of 800 ng of
PGE2 (P5640, Sigma-Aldrich, St. Louis, MO) in 50
microliters of 0.9% sodium chloride. Injections were per-
formed at 0,7,14, and 21 days. Animals were anesthe-
tized with isoflurane and the knees were shaved using
electric clippers. The skin was prepped with an alcohol
solution and the knee was flexed to 90 degrees to ten-
sion the tendon. The tendon was then injected parallel
thru its length to a point midway between the patella
and tibial insertions [7]. The India ink of practice injec-
tions in cadavers was found to distribute superficially
from the tendon, but stay beneath the peritenon. Thus,
while the injection was intratendinous it may better be
described as peritendinous. Animals were returned to
their cages and allowed food, water, and activity ad libi-
tum. All groups were sacrificed at 28 days, except the
PGE2-8 wks group which was sacrificed at 56 days.
Activity Monitoring
In order to determine if there was some disability related
to the injections or PGE2, we monitored animal activity
relative to pre-injection levels. This was completed for 6
animals in the saline group and 6 animals in the PGE2-8
wks group. We used a photoelectric sensors system to
monitor animal activity [9]. The rats were housed in indi-
vidual cages with the water source on one end and food
on the other end. The photoelectric sensor (Q14, Banner
Engineering, Minneapolis, MN) was set-up to bisect the
mid-portion of the cage. The sensors were linked to a con-
trol module (Logo!, Siemens, New York, NY) that
recorded a count each time the beam was crossed. One
count was recorded each time the animal stepped into and
subsequently out of the beam with a one-second delay.
Total counts were recorded at daily intervals for the dura-
tion of the study. The seven daily counts across a week’s
interval were averaged to compute an average daily count
for each week. The pre-injection daily count measurement
was taken as the average of the daily activity counts during
the 5 days pre-injection. The average daily count was used
in the statistical analysis.
Specimen Preparation
All animals were sacrificed by CO2 overdose and both
hind limbs harvested. Half of the right specimens (N = 5
per group) were transferred to 10% neutral buffered for-
malin, sequentially decalcified, dehydrated, embedded in
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plastic, sectioned, stained with hematoxylin and eosin,
and qualitatively examined for fiber arrangement and cel-
lularity. The remaining right limb specimens were fixed
for fibril diameter analysis. The left hind limb were
placed in saline-soaked gauze and stored at -20°C until
the time of mechanical testing. On the day of biomecha-
nical testing, the quadriceps, patella, patellar tendon, and
tibia were isolated and dissected free of other soft tissues.
Mechanical Testing
The length of the tendon as viewed from the anterior side
was measured using a digital micrometer. The cross sec-
tional area of the tendon at its midpoint was measured
using an area micrometer after 0.12 MPa of compression
was applied for 2 minutes. Measurements were taken in
triplicate and averaged. Spray irrigation with saline was
used to keep the tissue moist during all procedures. Fol-
lowing dissection and measurement, the tibia was secured
in a custom grip on a servohydraulic testing machine
(8500; Instron, Norwood MA). The quadriceps muscle
and tendon were secured in a custom designed cryogrip
and the visible freeze line edge of the tissue was allowed to
migrate to the superior edge of the patella. The tendon
was preloaded to 0.5 N and then the complex was loaded
to failure at a constant deformation rate of 0.08 mm/sec
corresponding to a 1% strain rate per second. The load-
deformation data was acquired via an analog to digital
converter linked to a personal computer and the failure
site was recorded. The structural properties of maximum
load, linear stiffness between 25-75% load limits, energy
absorbed, and deformation at ultimate load were deter-
mined as well as the corresponding material properties.
Biochemical Analysis
Following the biomechanical testing, the patellar tendon
was harvested and stored at -20°C. At the time of evalua-
tion, the tissue was thawed and then dehydrated. Dry
weight was recorded and the tissue was then subjected to
papain digestion (0.5 mg/ml, Sigma-Aldrich, St. Louis,
MO) in a 0.1 M phosphate buffer (pH 7) with 10 mM
Cystine HCL & 2 mM EDTA at 60°C for 6 hours. The
digest was used for the determination of collagen content.
Collagen content of the digest was measured by hydroxy-
proline concentration by the method of Bergman & Loxley
with a plate reader [13]. Standard curves were created
using known concentrations of hydroxyproline (Sigma-
Aldrich, St. Louis, MO).
Fibril Diameter Analysis
Tendons for this analysis (n = 5 per group for the control
and PGE2-8 wks groups) were fixed in 2% paraformalde-
hyde/2.5% glutaraldehyde in 0.15 M sodium phosphate
buffer, pH 7.4, for 24 hours followed by post-fixation in
1% osmium tetroxide in 0.15 M sodium phosphate buffer,
pH 7.4, for 1 hour. Samples were dehydrated in a graded
series of ethanols, followed by propylene oxide, and infil-
trated and embedded in Polybed 812 resin (Polysciences,
Inc., Warrington, PA). Tendon cross sections of 70 nm
thickness were stained with 6% methanolic uranyl acetate
and Reynolds’ lead citrate. Sections were observed using a
LEO EM-910 transmission electron microscope operating
at 80 kV (Carl Zeiss SMT, Peabody, MA) and images were
taken using a Gatan Orius SC1000 CCD camera with
Digital Micrograph 3.11.0 (Gatan, Inc., Pleasanton, CA).
Two regions of interest of (approximate size of 1.26 μm ×
1.05 μm) from each of three images (approximate size of
5.41 μm × 3.84 μm) of each animal were used to compute
the average fibril diameter. Fibril diameters were measured
for all fibrils in the region of interest using a custom script
written in a commercially available image analysis pro-
gram (Vision 6.0, National Instruments Inc., Austin, TX).
Statistical Analysis
Biomechanical parameters, collagen content, and collagen
fibril diameters were evaluated with a one way ANOVA,
followed by Holm-Sidak multiple comparison testing.
Activity counts from preinjection to 8 weeks were ana-
lyzed using a two-way repeated measures ANOVA for the
factors of time (repeated factor) and group.
Results
Forty animals were included in the study. One animal was
excluded from biomechanical testing in the PGE2-8 wks
groups due to tissue damage during dissection and five
specimens were excluded because the tensile failure
occurred at the quadriceps insertion of the patella during
biomechanical testing. The remaining specimens failed at
the patellar tendon insertions at either the tibial tubercle
(T) or patella (P). The failure site distribution for each
group was as follows: Control (6P, 1T), Saline (7P, 2T),
PGE2-4wks (7P, 2T), PGE2-8 wks (6P, 3T).
The ultimate load of the tendons in the PGE2-4 wks
were significantly greater than the control and the
sodium chloride injected tendons (Figure 1) (P < 0.05).
The ultimate tensile stress was not significantly different
between groups though the PGE2 groups showed a trend
to be stronger than the sodium chloride injected group
(Table 1). The PGE2-8 wks group tendons had signifi-
cantly greater structural stiffness than the control and
the sodium chloride injected tendons (Figure 1) (P <
0.05). The PGE2-8 wks group tendons also displayed a
significantly greater elastic modulus than the control and
the sodium chloride injected tendons (Table 1). In addi-
tion, the PGE2-8 wks group tendons displayed signifi-
cantly less deformation prior to the ultimate load
compared to the control tendons (Table 2 P < 0.05) and
a trend for a similar effect for the strain at ultimate load
(Table 1). Finally, a significant increase in the cross
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sectional area of the tendons in the sodium chloride
injected and PGE2-4 wks tendon as compared to the con-
trol tendons (P < 0.05) (Table 2) was found. There were
no significant differences between groups with respect to
length, energy absorbed or energy density (Tables 1 & 2).
There were no differences between initial or final body
weights for animals between groups.
There was a significant decrease in average daily activ-
ity counts from the pre-injection counts for the post-
injection times of 1, 2, 3, and 4 weeks independent of
group (Figure 2) (P < 0.05). There was no significant dif-
ference in activity counts between the PGE2 and saline
injected tendons. There was also no difference in activity
counts in the PGE2 injected animals at 0 weeks com-
pared to 8 weeks and at 4 weeks compared to 8 weeks.
No difference in collagen content was found between
the groups (Figure 3). The specimen numbers for the col-
lagen content evaluations were Control(9), Saline(4),
PGE2-4 wks(7), PGE2-and 8 wks (10). Fibril diameter
analysis of the control and PGE2-8 wks groups revealed
no difference in mean fibril diameter (Figure 4) between
these groups. Histologic specimens demonstrated signifi-
cant sectioning and orientation artifact that precluded a
quantitative analysis. In the zones free of section artifact
that were located more centrally or distally within the
tendon it was qualitatively observed that there were no
signs of collagen fiber disorganization or degeneration in
the PGE2 injected tissue (Figure 5).
Discussion
The results from our study did not support the hypothesis
that the biomechanical properties would be inferior after
PGE2 injection, rather, PGE2 appeared to produce the
opposite effect. In our study the local application of PGE2
improved the structural strength and structural/material
stiffness properties of the tendon. The increase in stiffness
was sustained 4 weeks after the injections were stopped at
4 weeks suggesting these improvements were not transi-
ent. The increase in cross-sectional area of the PGE2-4
wks tendons suggests that this improvement in structural
properties initially resulted from tendon hypertrophy. This
hypertrophy corresponds with recent work that has shown
that inhibition of PGE2 production in vivo can block exer-
cise-induced increases in collagen synthesis of the patellar
tendon in humans [11]. In addition, past work has shown
local PGE2 administration to increase fibrous tissue forma-
tion in muscle in an in vivo rabbit model [12]. The
improvement in stiffness in the PGE2-8 wks tendons of
our study may have been due material changes as the elas-
tic modulus was increased. However, material changes
were not detected in the collagen content or mean fibril
diameter evaluations.
There are several possible explanations for the differ-
ence in tissue response observed in this study compared
to the hypothesized degenerative tissue response based
on previous reports [6,7]. Our model may not have
shown the degenerative effects if the dosage of PGE2 was
inadequate, if the tendon was not exposed to PGE2 for a
long enough time, or if the testing was completed at too
early or late of a time point. The PGE2 injection model is
likely an oversimplification of the complexity of clinical
tendinopathy, and it is possible that administration of
PGE2 in concert with exercise loading or additional
inflammatory mediators that are upregulated with
mechanical loading may lead to a tendon with degenera-
tive properties. The dosage of PGE2 used in our study
was similar to that used in a previous rabbit patellar
Figure 1 Ultimate tensile load and stiffness of the rat patellar
tendon was increased with PGE2 injection. * Significant
difference vs. control.(P < 0.05) # Significant difference vs. saline
injected group. (P < 0.05).
Table 1 Material properties of the rat patellar tendon for the 4 groups (Mean ± SD)
Group Ultimate Stress (MPa) Strain to Ultimate Load (mm/mm) Elastic Modulus (MPa) Energy Density to Ultimate Load (mJ/mm3)
Control 26.2 ± 6.8 0.34 ± 0.08 84.5 ± 23.2 4.66 ± 2.38
Saline 21.6 ± 4.7 0.28 ± 0.06 83.2 ± 17.1 3.14 + 0.98
PGE2-4 wks 27.1 ± 5.3 0.31 ± 0.09 90.0 ± 18.2 4.47 + 1.67
PGE2-8 wks 28.2 ± 5.9 0.24 ± 0.05 124.0 ± 35.0*,#,+ 3.96 ± 1.22
F-test P = 0.091 P = 0.053 P = 0.004 P = 0.226
* Indicates difference from control group (P < 0.05) # Indicates difference from saline-injected group (P < 0.05).+ Indicates difference from PGE2-4 wks injection
group (P < 0.05).
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tendon study observing a degenerative tissue response to
PGE2 injection [6,7]. It is possible that with the larger
volume of the rabbit patellar tendon compared to the rat,
the injected PGE2 solution may have had a greater pro-
pensity to remain intratendinously causing a greater
effect on the internal fibroblasts and collagen fibrils. In
our study some of the injection solution was observed to
leak from the tendon, but stay beneath the peritenon.
Thus, the internal fibroblast may have been exposed to
lower concentrations of PGE2 than desired. This may
have contributed to the lack of change in fibril diameter
and matrix organization observed in this study as com-
pared to previous work [7]. If the collagen fibril changes
to PGE2 injection reported in the previous rabbit patellar
tendon model were a transient response, the slower rate
of metabolism in the rabbit compared to the rat may
have resulted in these changes dissipating prior to our
examination in our rat model. The timing of our evalua-
tion in our study was more extended than previous ani-
mal studies [6,7]. This might suggest that previously
reported histological changes may not have been degen-
erative changes but simply transient effects in the tissue
prior to obtaining its superior structural properties.
An alternative explanation for our results is that the
PGE2 production with tendon loading actually plays a
positive role in stimulating tendon remodeling and that
PGE2 alone is not the primary component of the patho-
logic development of tendinopathy. In support of PGE2’s
positive role in stimulating tendon remodeling, recent
studies have shown that inhibitors of prostaglandin pro-
duction, cyclooxgenase (COX) inhibitors, can impair the
tensile strength of healing tendon tissue after transec-
tion injury [8,9]. In interpreting these COX inhibitor
studies it is important to consider that these studies do
not simply involve reduction of PGE2, but can also
influence other elements of arachidonic acid metabolism
such as the production of leukotreines and PGD2
[2,3,14]. Furthermore, the timing of the administration
of COX inhibitors during tendon healing appears to be
important as early administration appears to impair
healing while delayed administration may improve the
material properties of the tissue [15]. It is also important
to note that a number of in vitro studies of human ten-
don fibroblasts from healthy tissue have demonstrated
negative effects of exogenous PGE2 exposure on prolif-
eration, collagen synthesis, and tendon stem cell differ-
entiation [5,16]. In contrast, the findings of in vitro
studies investigating the effect of COX inhibitors on
tendon fibroblasts would suggest the opposite effect of
PGE2 on proliferation as such inhibitors have been
found to decrease cell proliferation [17,18]. There will
always be some uncertainty regarding whether the
Table 2 Structural properties of the rat patellar tendon for the 4 groups (Mean ± SD)
Group Energy to Ultimate Load (J) Displacement at Ultimate Load (mm) Length (mm) Cross-sectional area (mm2)
Control 0.116 ± 0.053 2.64 ± 0.65 7.72 ± 0.57 3.30 ± 0.43
Saline 0.096 ± 0.028 2.18 ± 0.44 7.70 ± 0.25 3.98 ± 0.50*
PGE2-4 wks 0.132 ± 0.032 2.42 ± 0.65 7.81 ± 0.30 4.02 ± 0.75*
PGE2-8 wks 0.105 ± 0.029 1.87 ± 0.31* 7.66 ± 0.26 3.49 ± 0.28
F-test P = 0.187 P = 0.036 P = 0.83 P = 0.021
* Indicates difference from control group (P < 0.05)
Figure 2 Average daily activity counts across weekly intervals
for the animals. Counts at week zero were collected before
injections were started. Injections stopped after 3 weeks in the
PGE2-8 wk group. * Significant difference from week 0 (pre-
injection) counts independent of group.(P < 0.05).
Figure 3 Collagen content of the rat patellar tendon tissue did
not differ among the 4 groups (P > 0.05).
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mechanical and biochemical environment of the in vitro
setting are representative of the in vivo setting of tendon
healing. Recent work has shown that cultured tendon
cells of intact tendon do not demonstrate the same cel-
lular activity as healing tendon cells [19]. Furthermore,
in vivo microdialysis studies examining the effect of
COX inhibition on exercise-induced collagen synthesis
would suggest that PGE2 increases collagen synthesis
[11] as contrasted with in vitro work which suggests
PGE2 decreases collagen synthesis [5]. Finally, past stu-
dies have shown that the injection of fatty acid prepara-
tions that are similar to the arachidonic acid precursors
Figure 4 Representative transmission electron microscopy images of the cross-section of the rat patellar tendon. Image (A) is for a
control rat and image (B) is for a PGE2-8 wk treated rat. Scale bar of the electron micrographs = 500 nm. The mean fibril diameter (Mean ± SD)
of the rat patellar tendons (n = 5) was found to be similar (P > 0.05) in the control (154 ± 45) and PGE2-8 wks (167 ± 50) groups.
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of prostaglandins can increase the strength of ligament
and tendon [20,21]. Thus, it is apparent from these stu-
dies there still exists a great amount of uncertainty
regarding the effects of PGE2 on tendon in vivo.
While there is little literature regarding the direct effect
of prostaglandins on the biomechanical properties of ten-
don and ligament, there is a substantial body of evidence
regarding the effects of prostaglandins on bone. Multiple
in vivo studies have demonstrated an anabolic effect on
bone with subcutaneous or systemic administration of
prostaglandins. These studies have demonstrated
increased bone formation in multiple sites with prosta-
glandin treatment as well as prevention of bone loss asso-
ciated with disuse, immobilization, and ovariectomy
[22-24]. Similar anabolic results have been found with
local delivery of prostaglandins to bone [25-27]. On a his-
torical note, it is important to recognize that the early in
vitro studies of prostaglandins on bone focused on its
resorption effects [28], while later it was realized that this
resorption activity was often followed by increased bone
formation that ultimately produced an increase in bone
mass. It is unclear if the extensive past focus on the nega-
tive effects of PGE2 on tendon has limited the considera-
tion of positive effects in tendon healing. While the
elevated level of PGE2 seen with cyclical loading and
exercise may contribute to the development of tendino-
pathy, our results suggests that they may play more of an
adaptive role in improving tendon strength, similar to
their role in bone remodeling.
Another factor which may explain how PGE2 may have
both positive and negative effects may be in the relative
expression of the cellular receptors which mediate the
response to PGE2. It is known that the cellular response
to PGE2 is mediated by four G-protein coupled EP recep-
tors. In bone, it has been shown that the EP2 and EP4
receptors regulate the anabolic response to PGE2 and
Figure 5 Representative images of hematoxylin and eosin stained patellar tendon sections from the 4 groups. The images show a lack
of change in the matrix organization for the different groups: A) Control, B) PGE2-4 wks rat1, C) PGE2-4 wks rat2, D) PGE2-8 wks. (scale bar =
500 μm).
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agonists to these receptors have been shown to accelerate
fracture healing [29]. It is unclear if the same EP recep-
tors are anabolic for tendon as for bone and how recep-
tor expression may change across stages of tendon
healing. Receptor-selective EP agonists may allow for the
positive effects of prostaglandins on tendon healing to be
more effectively harnessed.
Our study was not without limitations. Early time points
of evaluation were not included in the study and these
may have helped capture early but transient responses of
the tendon injections. Only one dosage was used, but this
was the same dosage that was used in a past study that
reported significant histological changes in tendon in a rat
model [6]. The method of PGE2 delivery, injection, may
have also contributed to the tendon response. Finally, our
sample size may not have provided us adequate power to
detect differences in all of the evaluation measures.
Despite these limitations, our study provided the novel
finding that weekly PGE2 injections for four weeks can
cause an improvement in the biomechanical properties of
tendon and these improvements can persist for 4 weeks
after ceasing injections. Future studies will have to better
determine the biophysical and biochemical mechanisms
by which the PGE2 injections caused the improvement in
biomechanical properties. Weekly injection of PGE2
alone in the rat patellar tendon model does not appear to
mimic clinical tendinopathy, and at this stage it appears
more study is needed before attempting to use a prosta-
glandin injection model to study treatments for human
tendinopathies.
Conclusions
Four weekly peritendinous injections of PGE2 to the rat
patellar tendon were not found to be an effective model
of clinical tendinopathy. In contrast, improved structural
properties of the patellar tendon were found after PGE2
injection. While PGE2 has been thought to have a con-
tributory role in the development of tendinopathy and
anti-inflammatory medications remain a common treat-
ment, our results suggest a positive role of PGE2 in ten-
don remodeling in some circumstances.
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